Clinical oncology : a journal of the Royal College of Radiologists
-
Clin Oncol (R Coll Radiol) · Jun 2009
Comparative StudyVolumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study.
Volumetric modulated arc therapy (VMAT) is a novel extension of intensity-modulated radiotherapy (IMRT) where an optimised three-dimensional dose distribution may be delivered in a single gantry rotation. This optimisation algorithm is the predecessor to Varian's RapidArc. The aim of this study was to compare the ability of conventional static nine-field IMRT (cIMRT) and VMAT to boost as much of the clinical target volume (CTV) as possible to 88.8Gy without exceeding organ at risk (OAR) dose-volume constraints. ⋯ VMAT is able to boost more of the CTV to >or=120% than cIMRT without contravening OAR dose constraints, and uses 48% fewer monitor units. Treatment times were 61% less than with cIMRT.
-
Clin Oncol (R Coll Radiol) · Jun 2009
Does intensity-modulated stereotactic radiotherapy achieve superior target conformity than conventional stereotactic radiotherapy in different intracranial tumours?
To compare the dosimetric outcome of various conventional stereotactic radiotherapy (SRT) techniques with intensity-modulated stereotactic radiotherapy (IMSRT) in brain tumours of varying shape, size, location and proximity to organs at risk (OARs). ⋯ DCA and SCF are preferred conventional SRT techniques in terms of target conformity and reduction of doses to OARs. The use of IMSRT_NCP further improves conformity and reduces doses to OARs in a range of brain tumours commonly considered for stereotactic irradiation.
-
Clin Oncol (R Coll Radiol) · May 2009
Change in urinary markers of osteoclast activity following palliative radiotherapy for bone metastases.
To examine the effect of radiotherapy for bone metastases on urinary markers of osteoclast activity. ⋯ Baseline levels of urinary markers could not predict which patient would benefit from palliative radiotherapy.
-
Clin Oncol (R Coll Radiol) · May 2009
Multicenter StudyDexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases: a phase II study.
Pain flare occurs in over one-third of patients receiving palliative radiotherapy for bone metastases. A single dose of dexamethasone can decrease the incidence of pain flare during the first 2 days immediately after radiotherapy. We conducted a phase II prospective study to investigate the prophylactic role of prolonged dexamethasone. ⋯ Dexamethasone is effective in the prophylaxis of radiotherapy-induced pain flare after palliative radiotherapy for bone metastases. Randomised studies are needed to confirm this finding.